Abstract CT127: A phase I study of cMET inhibitor bozitinib in patients with advanced NSCLC harboring <i>cMET</i> alterations
Jin‐Ji Yang(Guangdong Academy of Medical Sciences), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Xinru Mao(Huazhong University of Science and Technology), Renhua Guo(Sun Yat-sen University), Hepeng Shi, Shuyin Chen(Guangdong Medical College), Wei-Zhe Xue, Bin Gan(Guangdong Academy of Medical Sciences), Lin Wu(Materials Systems (United States)), Qing Zhou(Jiangnan University), Lu Zhang(Burning Rock Biotech (China)), Hao Liu(Wannan Medical College), Jun Zhao(Beijing Institute of Technology), Yun Fan(Zhejiang Cancer Hospital), Xuan Lin(Beijing Technology and Business University), Peilong Zhang, Huajun Chen(Guangdong Academy of Medical Sciences), Han Han‐Zhang(Burning Rock Biotech (China))
Cited by 18
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k